ADC Therapeutics raises $86.6M and resets its debt
Also: GenSight’s GS030 optogenetics trial in NEJM and a €1.0M raise; Pharvaris’ RAPIDe-3 HAE data in The Lancet.
ADC Therapeutics raises $86.6M and resets its debt Beitrag lesen »
Also: GenSight’s GS030 optogenetics trial in NEJM and a €1.0M raise; Pharvaris’ RAPIDe-3 HAE data in The Lancet.
ADC Therapeutics raises $86.6M and resets its debt Beitrag lesen »